The 2015 Clinical Guidelines for the Treatment and Prevention of Opportunistic Infections in HIV-Infected Koreans: Guidelines for Opportunistic Infections

키워드

참고문헌 (48)

1. "Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents"[URL]
2. JuneMyungKim, "Epidemiology and Clinical Features of HIV Infection", AIDS in Korea, 2003, pp.44(3), 363~370[DOI]
3. Safrin S, "Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group", Ann Intern Med, 124, pp.792~802 (1996)
4. Crothers K, "Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations", AIDS, 19, pp.801~805 (2005)
5. Nielsen TL, "Adjunctive corticosteroid therapy for Pneumocystis carinii pneumonia in AIDS: a randomized European multicenter open label study", J Acquir Immune Defic Syndr, 5, pp.726~731 (1992)
6. Black JR, "Clindamycin and primaquine therapy for mild-to-moderate episodes of Pneumocystis carinii pneumonia in patients with AIDS: AIDS Clinical Trials Group 044", Clin Infect Dis, 18, pp.905~913 (1994)
7. Smego RA Jr, "A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia", Arch Intern Med, 161, pp.1529~1533 (2001)
8. Zolopa A, "Early antiretroviral therapy reduces AIDS progression", death in individuals with acute opportunistic infections: a multicenter randomized strategy trial, 2009, pp.4, e5575~
9. Phair J, "The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group", N Engl J Med, 322, pp.161~165 (1990)
10. Schneider MM, "Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS Treatment Group", J Infect Dis, 171, pp.1632~1636 (1995)
11. 황정환, "Incidence and Risk Factors of Tuberculosis in Patients with Human Immunodeficiency Virus Infection", Journal of Korean Medical Science, 28(3), pp.374~377 (2013), 대한의학회
12. Akolo C, "Treatment of latent tuberculosis infection in HIV infected persons", Cochrane Database Syst Rev, pp.CD000171~ (2010)
13. Padayatchi N, "Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial", Int J Tuberc Lung Dis, 18, pp.147~154 (2014)
14. Borand L, "Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (ANRS 1295-CIPRA KH001 CAMELIA trial)", PLoS One, 9, pp.e90350~ (2014)
15. Luetkemeyer AF, "Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study", Clin Infect Dis, 57, pp.586~593 (2013)
16. Rex JH, "Resistance of Candida species to fluconazole", Antimicrob Agents Chemother, 39, pp.1~8 (1995)
17. Pappas PG, "Guidelines for treatment of candidiasis", Clin Infect Dis, 38, pp.161~189 (2004)
18. Vazquez JA, "Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection", HIV AIDS (Auckl), 2, pp.89~101 (2010)
19. de Wet N, "A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients", Clin Infect Dis, 39, pp.842~849 (2004)
20. Krause DS, "A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis", Clin Infect Dis, 39, pp.770~775 (2004)
21. Skiest DJ, "Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection", Clin Infect Dis, 44, pp.607~614 (2007)
22. Leenders AC, "Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis", AIDS, 11, pp.1463~1471 (1997)
23. Hamill RJ, "Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety", Clin Infect Dis, 51, pp.225~232 (2010)
24. Powderly WG, "A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome", N Engl J Med, 326, pp.793~798 (1992)
25. Fessler RD, "Management of elevated intracranial pressure in patients with Cryptococcal meningitis", J Acquir Immune Defic Syndr Hum Retrovirol, 17, pp.137~142 (1998)
26. Newton PN, "A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis", Clin Infect Dis, 35, pp.769~772 (2002)
27. Makadzange AT, "Early versus delayed initiation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa", Clin Infect Dis, 50, pp.1532~1538 (2010)
28. Boulware DR, "Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis", N Engl J Med, 370, pp.2487~2498 (2014)
29. Powderly WG, "A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group", N Engl J Med, 332, pp.700~705 (1995)
30. 임혜미, "Serologic Survey of Toxoplasmosis in Seoul and Jeju-do, and a Brief Review of Its Seroprevalence in Korea", The Korean Journal of Parasitology, 50(4), pp.287~293 (2012), 대한기생충학ㆍ열대의학회
31. Katlama C, "Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS", Clin Infect Dis, 22, pp.268~275 (1996)
32. Béraud G, "Cotrimoxazole for treatment of cerebral toxoplasmosis: an observational cohort study during 1994-2006", Am J Trop Med Hyg, 80, pp.583~587 (2009)
33. Luft BJ, "Outbreak of central-nervous-system toxoplasmosis in western Europe and North America", Lancet, 1, pp.781~784 (1983)
34. Miro JM, "Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy:results of an open, randomized, multicenter clinical trial", Clin Infect Dis, 43, pp.79~89 (2006)
35. Carr A, "Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS", Ann Intern Med, 117, pp.106~111 (1992)
36. Mussini C, "Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study", J Infect Dis, 181, pp.1635~1642 (2000)
37. Holland GN, "AIDS and ophthalmology: the first quarter century", Am J Ophthalmol, 145, pp.397~408 (2008)
38. Martin DF, "Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group", N Engl J Med, 340, pp.1063~1070 (1999)
39. Jabs DA, "Longitudinal study of the ocular complications of AIDS: 1. Ocular diagnoses at enrollment", Ophthalmology, 114, pp.780~786 (2007)
40. Nguyen QD, "Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy", Am J Ophthalmol, 129, pp.634~639 (2000)
41. Morrison VL, "Intravitreal triamcinolone acetonide for the treatment of immune recovery uveitis macular edema", Ophthalmology, 114, pp.334~339 (2007)
42. Spector SA, "Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group", N Engl J Med, 334, pp.1491~1497 (1996)
43. Safrin S, "Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients", Antimicrob Agents Chemother, 38, pp.1246~1250 (1994)
44. Buchbinder SP, "Herpes zoster and human immunodeficiency virus infection", J Infect Dis, 166, pp.1153~1156 (1992)
45. Balfour HH Jr, "Acyclovir halts progression of herpes zoster in immunocompromised patients", N Engl J Med, 308, pp.1448~1453 (1983)
46. Martínez E, "High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors", Clin Infect Dis, 27, pp.1510~1513 (1998)
47. Domingo P, "Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection", Am J Med, 110, pp.605~609 (2001)
48. Breton G, "Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy", Clin Infect Dis, 27, pp.1525~1527 (1998)

관련 논문AI추천